Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose Escalation of Nebulized Inhalation of HRS-9821 Suspension in Healthy Individuals and Multiple Doses in COPD Patients
Latest Information Update: 23 May 2025
At a glance
- Drugs HRS 9821 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Guangdong Hengrui Pharmaceutical
Most Recent Events
- 14 May 2025 Status changed from recruiting to active, no longer recruiting.
- 08 May 2025 The protocol has been amended to change the inclusion criteria for subjects; now patients and healthy volunteers can participate with males and females.
- 08 May 2025 Planned number of patients changed from 134 to 130.